Skip to content

Inspection Record

Fin Vector Oy — FDA 483 Findings

US FDAInspected 2022-09-27Published 2026-10-26 4 findingsEquipment and facilityDeviation, CAPA, and investigationValidation and qualification

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Equipment used to support the manufacturing process is not maintained at appropriate intervals to prevent malfunctions, making the equipment unavailable for its intended use for equipment (b) (4) I Specifically, a.

2Equipment and facility

requency to confirm the (b) (41= currently has no requirements for (b) (4) Equipment used to clean drug product not adequately maintained.

3Deviation, CAPA, and investigation

The Quality System procedure for deviations and incidents allows for planned deviations to document a departure from a previously approved process as stated below: SOP - version 16, effective September 7, 2022, states in step 5.1, deviation may also be raised to document planned departure from written procedure or previously approved process.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Fin Vector Oy findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.